| 1 |
NCT03481933 |
Not yet recruiting
New |
Evaluation of a Transcranial Stimulation With Direct Current on Language Disorders in Semantic Dementia |
|
- Device: Transcranial stimulation
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Significant improvement of semantic performances on the experimental 'semantic matching test'
- Significant modulation of semantic performances on the 'semantic matching test'
- significant modulation of cortical metabolism and functional connectivity
- Detection of a potential outcome difference between left-excitatory and right-inhibitory tDCS
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT03481933 |
P160937J |
STIM-SD |
March 2018 |
August 2021 |
August 2021 |
March 29, 2018 |
March 29, 2018 |
|
- Département de Neurologie - Centre des maladies neurologiques, cognitives et comportementales
Paris, France - Hôpital de la Pitié-Salpétrière
Paris, France
|
| 2 |
NCT03260920 |
Recruiting |
Intranasal Oxytocin for Frontotemporal Dementia |
|
|
Interventional |
Phase 2 |
- Lawson Health Research Institute
- Weston Foundation
- Canadian Institutes of Health Research (CIHR)
- Berry Consultants
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Neuropsychiatric Inventory (NPI) apathy/indifference domain score
- Change in emotional facial expression recognition performance
- Change in the Revised Self-Monitoring Scale score
- Change in modified Clinicians Global Impression of Change (apathy) scores
|
112 |
All |
30 Years to 80 Years (Adult, Senior) |
NCT03260920 |
FTDOXY17EF |
FOXY |
January 31, 2018 |
September 1, 2021 |
September 1, 2021 |
August 24, 2017 |
February 5, 2018 |
|
- UCLA
Los Angeles, California, United States - UCSF
San Francisco, California, United States - Johns Hopkins University
Baltimore, Maryland, United States - (and 8 more...)
|
| 3 |
NCT01386333 |
Completed |
Safety Study of Intranasal Oxytocin in Frontotemporal Dementia |
|
- Drug: oxytocin
- Drug: Saline Nasal Mist
|
Interventional |
Phase 1 |
- Lawson Health Research Institute
- Consortium of Canadian Centres for Clinical Cognitive Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- Neuropsychiatric Inventory
- Frontal Behavioural Inventory
- (and 4 more...)
|
23 |
All |
30 Years to 80 Years (Adult, Senior) |
NCT01386333 |
R-11-232
17783 |
FTDOXY10EF |
June 2011 |
October 2013 |
|
July 1, 2011 |
November 4, 2013 |
|
- Cognitive Neurology and Alzheimer Research Centre
London, Ontario, Canada
|
| 4 |
NCT01937013 |
Recruiting |
Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia |
|
- Drug: Intranasal oxytocin
- Drug: Saline Nasal Mist
|
Interventional |
Phase 2 |
- Lawson Health Research Institute
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Functional magnetic resonance imaging (fMRI) BOLD signal
- Cognitive and Emotional Task performance
|
72 |
All |
30 Years to 85 Years (Adult, Senior) |
NCT01937013 |
R-13-270
166786
103555
FTDOXY13EF |
IEMO |
September 2013 |
March 2018 |
March 2018 |
September 9, 2013 |
March 10, 2017 |
|
- Parkwood Hospital
London, Ontario, Canada
|
| 5 |
NCT03371706 |
Recruiting |
Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia |
- Primary Progressive Aphasia
|
- Behavioral: Evidence-Based Treatment
|
Interventional |
Not Applicable |
- Northwestern University
- National Institute on Aging (NIA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Language Performance Measures
|
90 |
All |
30 Years to 100 Years (Adult, Senior) |
NCT03371706 |
STU00206086
1R01AG055425-01A1 |
|
April 3, 2018 |
February 1, 2023 |
February 1, 2024 |
December 13, 2017 |
April 4, 2018 |
|
- Cognitive Neurology and Alzheimer's Disease Center - Northwestern University
Chicago, Illinois, United States
|
| 6 |
NCT00537004 |
Recruiting |
Language in Primary Progressive Aphasia |
- Primary Progressive Aphasia
|
|
Observational |
|
- Northwestern University
- National Institute on Deafness and Other Communication Disorders (NIDCD)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Neuropsychological variables
|
300 |
All |
Child, Adult, Senior |
NCT00537004 |
IA0125
R01DC008552 |
|
May 2007 |
April 2022 |
April 2023 |
September 28, 2007 |
September 13, 2017 |
|
- Northwestern University
Chicago, Illinois, United States
|
| 7 |
NCT02372773 |
Recruiting |
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects |
- Familial Frontotemporal Dementia
|
|
Observational |
|
- Mayo Clinic
- National Institute on Aging (NIA)
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Rate of decline in traditional measures of clinical (neuropsychological and behavioral composites) function and cortical volume on structural MRI in the symptomatic phase of familial FTD
- Rate of decline in traditional measures of clinical (neuropsychological and behavioral composites) function and cortical volume on structural MRI in the asymptomatic phase of familial FTD
- Value of novel imaging and clinical measures for characterizing asymptomatic familial FTD subjects, and factors predicting clinical rates of progression in each group.
- Genetic and biofluid factors that modify rates of clinical and neuroimaging decline in the asymptomatic and symptomatic phases of familial FTD.
|
300 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02372773 |
14-007532
U01AG045390 |
LEFFTDS |
April 2015 |
April 2019 |
April 2019 |
February 26, 2015 |
January 29, 2018 |
|
- University of California, San Francisco, Memory and Aging Center, Department of Neurology
San Francisco, California, United States - Mayo Clinic Florida
Jacksonville, Florida, United States - Harvard University
Charlestown, Massachusetts, United States - (and 5 more...)
|
| 8 |
NCT00594737 |
Completed |
Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia |
|
- Drug: memantine hydrochloride
|
Interventional |
Phase 3 |
- Tiffany Chow, MD
- H. Lundbeck A/S
- Rotman Research Institute at Baycrest
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Metabolic activity in frontal and temporal lobes.
- Behavioural inventories, UPDRS Motor scale.
|
17 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT00594737 |
Baycrest.Ebixa.FTD-001
Lundbeck 11627A |
|
October 2007 |
June 2012 |
June 2012 |
January 16, 2008 |
June 4, 2012 |
|
- Baycrest
Toronto, Ontario, Canada
|
| 9 |
NCT02124083 |
Completed
Has Results |
Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 |
|
|
Interventional |
Phase 1
Phase 2 |
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Washington University School of Medicine
- Weill Medical College of Cornell University
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Tolerabilty of 200 mg Vorinostat in Niemann-Pick Disease, Type C1
- Number of Participants With Tolerabilty of 400 mg Vorinostat in Niemann-Pick Disease, Type C1
- Biochemical Efficacy as Measured by Serum Cathepsin D
- Biochemical Efficacy as Measured by Serum LGALS3
|
12 |
All |
18 Years to 60 Years (Adult) |
NCT02124083 |
140102
14-CH-0102 |
|
April 25, 2014 |
December 13, 2016 |
December 13, 2016 |
April 28, 2014 |
February 22, 2018 |
February 22, 2018 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 10 |
NCT02736695 |
Recruiting |
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia |
- Primary Progressive Aphasia
|
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- The investigators will be looking at the amount of Tau protein in the brain of patients with PPA.
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT02736695 |
16-001703 |
SLD3 |
July 2016 |
June 2018 |
June 2018 |
April 13, 2016 |
March 20, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
| 11 |
NCT01899950 |
Completed |
Longitudinal Study of Cognition With Niemann-Pick Disease, Type C |
- Niemann-Pick Disease, Type C
|
|
Observational |
|
- Mayo Clinic
- Rare Diseases Clinical Research Network
- National Center for Advancing Translational Science (NCATS)
- (and 2 more...)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Composite score of neurocognitive measures
|
70 |
All |
2 Years to 99 Years (Child, Adult, Senior) |
NCT01899950 |
11-003868
U54NS065768
LDN6715 |
NPC |
March 2011 |
September 2014 |
September 2014 |
July 16, 2013 |
January 6, 2016 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
| 12 |
NCT01626378 |
Completed |
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) |
- Behavioral Variant Frontotemporal Dementia (bvFTD)
|
- Drug: TRx0237
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline on Addenbrooke's Cognitive Examination - Revised (ACE-R)
- Change from Baseline on Functional Activities Questionnaire (FAQ)
- Change from Baseline on whole brain volume (assessed by brain MRI)
- (and 4 more...)
|
220 |
All |
up to 79 Years (Child, Adult, Senior) |
NCT01626378 |
TRx-237-007 |
|
May 2013 |
February 2016 |
February 2016 |
June 22, 2012 |
March 14, 2018 |
|
- David Geffen School of Medicine at UCLA, UCLA Neurological Services
Los Angeles, California, United States - The Shankle Clinic
Newport Beach, California, United States - Memory and Aging Centre
San Francisco, California, United States - (and 64 more...)
|
| 13 |
NCT00376051 |
Completed |
Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia |
|
|
Interventional |
Phase 4 |
- Sunnybrook Health Sciences Centre
- Alzheimer Society of Canada
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Neuropsychiatric Inventory (NPI)
- Frontal Behavioural Inventory (FBI)
- Clinical Global Impression (CGI)
- (and 3 more...)
|
22 |
All |
18 Years and older (Adult, Senior) |
NCT00376051 |
218-2006
07-48 |
|
September 2006 |
July 2009 |
September 2009 |
September 14, 2006 |
May 5, 2017 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada - The Baycrest Centre for Geriatric Care
Toronto, Ontario, Canada
|
| 14 |
NCT01002300 |
Completed |
Oxytocin and Social Cognition in Frontotemporal Dementia |
- Frontotemporal Dementia
- Pick's Disease
|
- Drug: intranasal oxytocin
|
Interventional |
Not Applicable |
- Lawson Health Research Institute
- The Alzheimer Society London and Middlesex
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Performance on Emotion Recognition Tasks
- Behavioural Ratings of Emotional Sensitivity and Repetitive Behaviours
- Side effects
|
24 |
All |
30 Years to 80 Years (Adult, Senior) |
NCT01002300 |
R-08-395
15398 |
|
September 2009 |
November 2010 |
November 2010 |
October 27, 2009 |
March 18, 2014 |
|
- Cognitive Neurology and Alzheimer's Research Centre, St. Joseph's Hospital
London, Ontario, Canada
|
| 15 |
NCT03088956 |
Recruiting |
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD) |
- Frontotemporal Dementia
- Behavioral Variant Frontotemporal Dementia
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Annualized rate of change in International Shopping List Test (ISLT) - Immediate Recall
- Annualized rate of change in Detection Test
- Annualized rate of change in Identification Test
- (and 57 more...)
|
70 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03088956 |
992FD001 |
FORWARD |
January 19, 2018 |
February 27, 2019 |
March 27, 2019 |
March 24, 2017 |
April 17, 2018 |
|
- Research Site
Birmingham, Alabama, United States - Research Site
Los Angeles, California, United States - Research Site
San Francisco, California, United States - (and 7 more...)
|
| 16 |
NCT00674960 |
Unknown † |
Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia |
- Pick Disease of the Brain
|
- Radiation: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
|
Interventional |
Phase 1 |
- GAAD Medical Research Institute Inc.
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Therapy for FTD patients
- Rehabilitation of FTD Patients
|
0 |
All |
Child, Adult, Senior |
NCT00674960 |
GAAD-FD-CTP1 |
|
May 2008 |
May 2009 |
October 2009 |
May 8, 2008 |
August 17, 2009 |
|
- The Centre for Incurable Diseases
Toronto, Ontario, Canada
|
| 17 |
NCT00077896 |
Completed |
Direct Current Brain Polarization in Frontotemporal Dementia |
- Pick Disease of the Brain
|
- Procedure: Direct Current Polarization
|
Interventional |
Phase 1 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
6 |
All |
Child, Adult, Senior |
NCT00077896 |
040122
04-N-0122 |
|
February 2004 |
|
August 2005 |
February 13, 2004 |
March 4, 2008 |
|
- National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, United States
|
| 18 |
NCT02862210 |
Recruiting |
Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia |
- Frontotemporal Dementia (FTD)
|
- Drug: Lithium Carbonate
- Drug: Placebo
|
Interventional |
Phase 2 |
- Columbia University
- Alzheimer’s Drug Discovery Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Reduction in agitation and aggression as measured by the Neuropsychiatric Inventory Scale (NPI)
- Proportion of responders in the lithium and placebo groups
|
60 |
All |
40 Years to 85 Years (Adult, Senior) |
NCT02862210 |
NYSPI 7310 |
Lithium |
January 27, 2017 |
September 2019 |
March 2020 |
August 10, 2016 |
April 19, 2017 |
|
- Johns Hopkins University
Baltimore, Maryland, United States - Columbia University Medical Center
New York, New York, United States
|
| 19 |
NCT00545974 |
Completed
Has Results |
Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia |
- Frontal Lobe Dementia
- Frontotemporal Lobe Dementia
- Semantic Dementia
|
- Drug: memantine
- Drug: Placebo pill
|
Interventional |
Phase 4 |
- University of California, San Francisco
- Forest Laboratories
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Neuropsychiatric Inventory (NPI)
- Clinical Global Impression of Change (CGIC)
- CDR-FTD, MMSE, FAQ, TFLS, EXIT25, UCSF FTD-Neuropsychological Test Battery: CVLT, Verbal Fluency, Modified BNT, Backward Digit Span, Digit Symbol Test, Modified Trails B, Modified Unified Parkinson's Disease Rating Scale, Antipsychotic Therapy
|
81 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT00545974 |
NAM-53:memantineplacebo |
|
October 2007 |
December 2012 |
December 2012 |
October 18, 2007 |
February 5, 2014 |
February 5, 2014 |
- University of California, Los Angeles
Los Angeles, California, United States - University California, San Francisco
San Francisco, California, United States - Mayo Clinic - Jacksonville
Jacksonville, Florida, United States - (and 6 more...)
|
| 20 |
NCT00975689 |
Completed
Has Results |
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine |
- Niemann-Pick Disease, Type C
|
|
Interventional |
Phase 1
Phase 2 |
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- University of Oxford
- Washington University School of Medicine
- (and 2 more...)
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
|
35 |
All |
12 Months and older (Child, Adult, Senior) |
NCT00975689 |
090185
09-CH-0185 |
|
August 2009 |
November 2010 |
November 2010 |
September 11, 2009 |
May 6, 2013 |
July 12, 2012 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 21 |
NCT03471143 |
Recruiting |
Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C |
- Niemann-Pick Disease, Type C
|
- Drug: 2-Hydroxypropyl-Beta-Cyclodextrin
|
Interventional |
Phase 1
Phase 2 |
- Washington University School of Medicine
- Johns Hopkins University
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of VTS-270 to reduce plasma levels of glycine-conjugated trihydroxycholanic acid ("bile acid biomarker"), an NPC-specific pharmacodynamic biomarker.
- Effect of drug on serum transaminases
- Reduction of liver and/or spleen volumes
|
12 |
All |
up to 6 Months (Child) |
NCT03471143 |
201708114
1U01HD090845-01 |
|
March 2018 |
February 2022 |
February 2022 |
March 20, 2018 |
March 27, 2018 |
|
- St. Louis Children's Hospital
Saint Louis, Missouri, United States
|
| 22 |
NCT02435030 |
Completed |
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C |
- Niemann-Pick Disease, Type C
|
|
Observational |
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- NP-C clinical disease severity
- Quality of life questionnaire (EQ-5D-Y)
- Ultrasonographic evaluation of liver and spleen
- (and 4 more...)
|
35 |
All |
2 Years to 18 Years (Child, Adult) |
NCT02435030 |
CT-ORZY-NPC-001
2014-005194-37 |
|
September 2015 |
May 2017 |
May 2017 |
May 6, 2015 |
May 18, 2017 |
|
- University Hospital Copenhagen (Rigshospitalet)
Copenhagen, Denmark - CHU de Montpellier
Montpellier, France - Hôpital Trousseau
Paris, France - (and 13 more...)
|
| 23 |
NCT02506036 |
Unknown † |
Efficacy of Web-Based Social-Cognitive Interventions in Right Hemisphere Stroke and Frontotemporal Dementia |
- Frontotemporal Dementia
- Right Sided Cerebral Hemisphere Cerebrovascular Accident
|
|
Interventional |
Not Applicable |
- Johns Hopkins University
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Social-Cognitive Functioning from Baseline to 12 weeks
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02506036 |
IRB00061812 |
|
August 2015 |
August 2017 |
January 2018 |
July 22, 2015 |
April 8, 2016 |
|
- Johns Hopkins Hosptial
Baltimore, Maryland, United States
|
| 24 |
NCT00416169 |
Completed |
A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia |
- Frontotemporal Dementia
- Pick Complex
|
- Drug: galantamine hydrobromide
|
Interventional |
Phase 2 |
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The safety is incidence of gastrointestinal events; efficacy are FBI, AQ and CGI. Changes will be calculated from baseline to Week 18 and Week 26. Comparisons between the placebo and galantamine groups will use the changes from Weeks 18 to 26.
- Secondary efficacy parameters are: MMSE, MDRS, FAB, NPI, ADCS-ADL Scale, subscales of the WAB and FBI and neurologic exams; safety are AE, ECGs, physical exam, vital signs, and lab tests.
|
41 |
All |
30 Years to 80 Years (Adult, Senior) |
NCT00416169 |
CR003106 |
|
May 2003 |
|
July 2004 |
December 27, 2006 |
June 8, 2011 |
|
|
| 25 |
NCT00344331 |
Recruiting |
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C |
- Neimann-Pick Disease, Type C
|
|
Observational |
|
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Other
|
|
300 |
All |
Child, Adult, Senior |
NCT00344331 |
060186
06-CH-0186 |
|
June 19, 2006 |
|
|
June 26, 2006 |
April 24, 2018 |
|
- Kennedy Krieger Institute
Baltimore, Maryland, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - Washington University, St. Louis
Saint Louis, Missouri, United States
|
| 26 |
NCT02606422 |
Recruiting |
tDCS Intervention in Primary Progressive Aphasia |
- Primary Progressive Aphasia
- MCI
- FTD
|
- Device: Active tDCS plus Speech-Language Therapy
- Device: Sham plus Speech-Language Therapy
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in oral naming (trained items)
- Change in written naming (trained items)
- Change in oral naming (untrained items)
- (and 3 more...)
|
70 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT02606422 |
NIH/NIDCD R01DC014475 |
|
April 2013 |
April 2020 |
May 2020 |
November 17, 2015 |
December 7, 2017 |
|
- Johns Hopkins Hospital
Baltimore, Maryland, United States
|
| 27 |
NCT01890343 |
Completed
Has Results |
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. |
- Alzheimer's Disease
- Frontotemporal Dementia
|
- Drug: florbetapir 18F
- Drug: 18F-FDG
|
Interventional |
Phase 2 |
- Avid Radiopharmaceuticals
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Qualitative Amyloid Image Assessment
- Quantitative Amyloid Image Assessment
|
34 |
All |
45 Years and older (Adult, Senior) |
NCT01890343 |
18F-AV-45-010 |
|
September 2009 |
December 2012 |
April 2013 |
July 1, 2013 |
September 29, 2014 |
September 17, 2014 |
- Research Site
Manchester, United Kingdom
|
| 28 |
NCT00159198 |
Terminated |
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia |
- Frontotemporal Dementia
- Amyotrophic Lateral Sclerosis
|
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
|
400 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT00159198 |
CRC01107
P011023 |
|
September 2002 |
|
June 2007 |
September 12, 2005 |
September 8, 2008 |
|
- CHU de la Côte de Nacre
Caen, France - Centre Hospitalier Universitaire de Lille
Lille, France - Hôpital La Timone
Marseille, France - (and 12 more...)
|
| 29 |
NCT02245568 |
Terminated |
Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) |
- Alzheimer's Disease
- Behavioral Variant Frontotemporal Dementia
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with serious and non-serious adverse events
- Change from Baseline in laboratory test values
- Change from Baseline in vital signs
- Change from Baseline in electrocardiograms
|
913 |
All |
Child, Adult, Senior |
NCT02245568 |
TRx-237-020 |
|
August 2014 |
May 2017 |
May 2017 |
September 19, 2014 |
March 14, 2018 |
|
- Xenoscience, Inc / 21st Century Neurology
Phoenix, Arizona, United States - Southern California Research, LLC
Fountain Valley, California, United States - Feldman, Robert MD
Laguna Hills, California, United States - (and 133 more...)
|
| 30 |
NCT03422250 |
Recruiting |
Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia |
- Alzheimer Disease
- Frontotemporal Dementia, Behavioral Variant
|
- Device: transcranial direct current stimulation (tDCS)
|
Interventional |
Not Applicable |
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in clinical disease severity
- Change from baseline in behavioral symptom severity
- Change from baseline in functional connectivity
- (and 7 more...)
|
60 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT03422250 |
GR-2011-02349787 |
NetCogBs |
June 19, 2015 |
June 3, 2018 |
November 3, 2018 |
February 5, 2018 |
February 6, 2018 |
|
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Brescia, Italy
|
| 31 |
NCT03040713 |
Recruiting |
Flortaucipir PET Imaging in Subjects With FTD |
|
- Drug: 18F-AV-1451
- Drug: 18F-AV-45
|
Interventional |
Phase 1 |
- Avid Radiopharmaceuticals
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- 18F-AV-1451 tracer uptake measured by regional SUVr
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT03040713 |
18F-AV-1451-A19 |
|
April 11, 2017 |
December 2018 |
December 2018 |
February 2, 2017 |
January 9, 2018 |
|
- Movement Disorder Center, UCSD
La Jolla, California, United States - Memory and Aging Center, UCSF
San Francisco, California, United States - UT Southwestern Medical Center
Dallas, Texas, United States
|
| 32 |
NCT02928848 |
Completed |
Baseline Severity and tDCS in PPA |
- Primary Progressive Aphasia
|
- Device: transcranial direct current stimulation
|
Interventional |
Not Applicable |
- University of Pennsylvania
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Language assessment: Immediately post-stimulation
- Language assessment: Six weeks post-stimulation
- Language assessment: Twelve weeks post-stimulation
|
17 |
All |
45 Years to 80 Years (Adult, Senior) |
NCT02928848 |
818622 |
|
September 2014 |
October 2017 |
October 2017 |
October 10, 2016 |
December 8, 2017 |
|
|
| 33 |
NCT03406429 |
Not yet recruiting |
rTMS as a Treatment for PPA |
- Logopenic Variant Primary Progressive Aphasia
- Non-Fluent Primary Progressive Aphasia
|
- Device: Active rTMS
- Device: SHAM rTMS
|
Interventional |
Early Phase 1 |
- Brigham and Women's Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Language Assessment Battery
|
20 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03406429 |
2017P002319 |
|
March 1, 2018 |
January 1, 2020 |
January 1, 2021 |
January 23, 2018 |
January 23, 2018 |
|
|
| 34 |
NCT02939547 |
Recruiting |
Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1) |
- Niemann-Pick Disease, Type C1
|
- Drug: Hydroxypropyl-beta-cyclodextrin
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Maximum Concentration ( C max) of Trappsol in plasma from patients with Niemann-Pick disease Type C1 by measurement of plasma levels
- Time to Maximum Concentration (T max) of Trappsol in plasma from patients with Niemann-Pick disease Type C1 by measurement of plasma levels
- Volume of Distribution of Trappsol in plasma from patients with Niemann-Pick disease Type C1 by measurement of plasma levels
- (and 9 more...)
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT02939547 |
CTD-TCNPC-101 |
|
October 11, 2017 |
February 2019 |
February 2019 |
October 20, 2016 |
March 23, 2018 |
|
- UCSF Benioff Children's Hospital Oakland
Oakland, California, United States
|
| 35 |
NCT02912793 |
Recruiting |
Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1 |
- Niemann-Pick Disease, Type C1
|
- Drug: Hydroxypropyl-beta-cyclodextrin
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To evaluate the plasma the Maximum Concentration (C max) of 3 doses of Trappsol by measurement of plasma levels
- To evaluate the Time to Maximum Concentration ( Tmax) of 3 doses of Trappsol by measurement of plasma levels
- To evaluate the Volume of Distribution of Trappsol by measurement of plasma levels
- (and 9 more...)
|
12 |
All |
2 Years and older (Child, Adult, Senior) |
NCT02912793 |
CTD-TCNP-201 |
|
March 20, 2017 |
August 2019 |
August 2019 |
September 23, 2016 |
April 17, 2018 |
|
- Soroka Mc
Beer sheva, Rager Blvd, Israel - HaeMek MC
'Afula, Israel - Karolinska Trial Alliance
Solna, Huddinge, Sweden - (and 2 more...)
|
| 36 |
NCT01147679 |
Unknown † |
Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls |
- Frontotemporal Dementia
- Frontotemporal Degeneration
- Alzheimer's Disease
- Social Behavior
|
|
Observational |
|
- University of California, Los Angeles
- National Institute on Aging (NIA)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Psychophysiological Reactivity
- Behavioral Reports and Observations
- MRI Brain-Mapping
|
99 |
All |
40 Years to 75 Years (Adult, Senior) |
NCT01147679 |
1R01AG034499
UCLA IRB#10-001097
R01AG034499 |
|
January 2010 |
September 2013 |
July 2014 |
June 22, 2010 |
October 28, 2011 |
|
- UCLA Department of Neurology
Los Angeles, California, United States
|
| 37 |
NCT00410566 |
Terminated |
Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) |
- Acid Sphingomyelinase Deficiency
- Niemann-Pick Disease
|
|
Interventional |
Phase 1 |
- Genzyme, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety assessments via physical exam,AE reporting,telemetry heartrate monitoring,ECG,ECHO,clinical lab evaluations,liver and adrenal function tests,cytokine testing,adrenal hormone levels,lipid profile,chest Xrays,liver biopsies,MRI of internal
- Immune Response Measure
- PK measurements
|
11 |
All |
18 Years to 65 Years (Adult) |
NCT00410566 |
SPHINGO00605 |
|
December 2006 |
March 2009 |
April 2009 |
December 13, 2006 |
March 19, 2015 |
|
- New York, New York, United States
|
| 38 |
NCT00200538 |
Completed |
Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients |
|
|
Interventional |
Phase 2 |
- Nantes University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
52 |
All |
45 Years to 75 Years (Adult, Senior) |
NCT00200538 |
BRD 05/1-E |
|
September 2005 |
|
|
September 20, 2005 |
May 3, 2013 |
|
- Martine Vercelletto
Nantes, France
|
| 39 |
NCT02945774 |
Recruiting |
Molecular Neuroimaging of Neuroinflammation in Neurodegenerative Dementias |
|
|
Interventional |
Not Applicable |
- Lawson Health Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Group differences in regional PET FEPPA ligand imaging
- Correlation between PET FEPPA ligand images and specified MR images
|
40 |
All |
30 Years to 95 Years (Adult, Senior) |
NCT02945774 |
107561 |
|
August 2016 |
February 2020 |
August 2021 |
October 26, 2016 |
February 5, 2018 |
|
- Parkwood Institute
London, Ontario, Canada
|
| 40 |
NCT01760564 |
Completed |
Application of Miglustat in Patients With Niemann-Pick Type C |
- Niemann-Pick Disease Type C
|
|
Interventional |
Phase 3 |
- National Taiwan University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
5 |
All |
Child, Adult, Senior |
NCT01760564 |
200802043M |
|
January 2008 |
December 2010 |
December 2010 |
January 4, 2013 |
January 4, 2013 |
|
- National Taiwan University Hospital
Taipei, Taiwan
|
| 41 |
NCT02439853 |
Active, not recruiting |
Communication Bridge Speech Therapy Research Study |
- Primary Progressive Aphasia
- Frontotemporal Dementia
|
- Behavioral: Monthly Check-in Session
|
Interventional |
Not Applicable |
- Northwestern University
- Alzheimer's Association
- The Association for Frontotemporal Degeneration
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Assessment of Functional Communication Abilities
|
57 |
All |
Child, Adult, Senior |
NCT02439853 |
STU00073634 |
|
March 2013 |
December 2019 |
January 2021 |
May 12, 2015 |
November 17, 2017 |
|
- Northwestern University
Chicago, Illinois, United States
|
| 42 |
NCT02149160 |
Unknown † |
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation |
|
- Drug: FRM-0334
- Drug: Placebo
|
Interventional |
Phase 2 |
- FORUM Pharmaceuticals Inc
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Evaluate the safety and tolerability of FRM-0334
- Assess the pharmacodynamic (PD) effects of FRM-0334 on the change from baseline in plasma concentrations of progranulin (PGRN) after 28 days
- Assess the pharmacodynamic effects of FRM-0334 on the change from baseline in cerebrospinal fluid (CSF) concentrations of PGRN after 28 days
- (and 2 more...)
|
30 |
All |
21 Years to 75 Years (Adult, Senior) |
NCT02149160 |
FRM-0334-002
2014-001489-85 |
|
October 2014 |
August 2016 |
|
May 29, 2014 |
March 23, 2016 |
|
- UCSF Memory and Aging Center
San Francisco, California, United States - Compass Research, LLC
Orlando, Florida, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - (and 10 more...)
|
| 43 |
NCT02841358 |
Terminated |
Screening of Niemann-Pick Disease, Type C in a Psychiatric Population |
- Psychiatric Adults Patients
|
- Biological: Blood sampling
- Biological: Biopsy
|
Interventional |
Not Applicable |
- University Hospital, Grenoble
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
|
22 |
All |
18 Years and older (Adult, Senior) |
NCT02841358 |
38RC13.200 |
NPCPsy |
December 2013 |
June 2016 |
December 2016 |
July 22, 2016 |
January 13, 2017 |
|
- UniversityHospitalGrenoble
La Tronche, France
|
| 44 |
NCT02541097 |
Active, not recruiting |
Preventing Language Decline in Dementia |
- Primary Progressive Aphasia
|
- Behavioral: Language therapy
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Naming accuracy measured with standard naming tests (e.g., BNT)
|
20 |
All |
Child, Adult, Senior |
NCT02541097 |
NPSASA-15-362999 |
|
May 2016 |
April 2018 |
April 2018 |
September 4, 2015 |
June 23, 2017 |
|
- Baycrest Health Sciences
Toronto, Ontario, Canada
|
| 45 |
NCT01738386 |
Terminated |
Living With Frontotemporal Dementia |
|
|
Observational |
|
- National Human Genome Research Institute (NHGRI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Retrospective
|
|
16 |
All |
18 Years and older (Adult, Senior) |
NCT01738386 |
999912153
12-HG-N153 |
|
June 13, 2012 |
|
February 24, 2016 |
November 30, 2012 |
April 5, 2018 |
|
- Johns Hopkins University
Baltimore, Maryland, United States - Columbia University
New York, New York, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 46 |
NCT00957710 |
Completed |
Language Treatment for Progressive Aphasia |
- Primary Progressive Aphasia
- Nonfluent Progressive Aphasia
- Semantic Dementia
|
- Behavioral: Errorless learning
|
Interventional |
Not Applicable |
- Baycrest
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Accuracy of picture naming
- Changes on neuroimaging
|
7 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT00957710 |
REB 09-24 |
|
August 2009 |
July 2010 |
December 2010 |
August 12, 2009 |
January 27, 2015 |
|
- Baycrest
Toronto, Ontario, Canada
|
| 47 |
NCT02999282 |
Recruiting |
Rehabilitative Trial for the Rescue of Neurophysiological Parameters in Progranulin Deficient Subjects |
- Frontotemporal Dementia
- GRN Related Frontotemporal Dementia
|
- Device: Anodal transcranial direct current stimulation
- Device: Sham transcranial direct current stimulation
|
Interventional |
Not Applicable |
- Azienda Ospedaliera Spedali Civili di Brescia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in SICI measurements from Baseline
- Change in ICF measurements from Baseline
- Change in SICF measurements from Baseline
- Change in LICI measurements from Baseline
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT02999282 |
2441 |
ReRescuePGR |
October 31, 2016 |
June 30, 2018 |
September 30, 2019 |
December 21, 2016 |
February 10, 2017 |
|
- Azienda Ospedaliera Spedali Civili di Brescia
Brescia, Italy
|
| 48 |
NCT00604591 |
Active, not recruiting |
Effects of Tolcapone on Frontotemporal Dementia |
- Frontotemporal Lobar Degeneration
|
- Drug: Tolcapone
- Drug: Placebo
|
Interventional |
Phase 2 |
- Columbia University
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Reaction time on the most difficult N-back condition that the patients can successfully perform.
- A difference in the normalized BOLD signal intensity between subjects on placebo vs. tolcapone.
|
28 |
All |
40 Years to 85 Years (Adult, Senior) |
NCT00604591 |
AAAF4151
5R00NS060766 |
|
July 2011 |
August 2015 |
October 2016 |
January 30, 2008 |
June 16, 2016 |
|
- Columbia University Medical Center, 622 West 168th Street
New York, New York, United States
|
| 49 |
NCT01747135 |
Completed |
Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease |
- Niemann-Pick Disease, Type C1
|
|
Interventional |
Phase 1 |
- Vtesse Inc.
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 24-hydroxycholesterol Area under the curve
- Hearing loss.
|
14 |
All |
2 Years to 25 Years (Child, Adult) |
NCT01747135 |
130001
13-CH-0001 |
|
January 2013 |
March 2017 |
March 2017 |
December 11, 2012 |
April 19, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 50 |
NCT02873546 |
Recruiting |
tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia |
- Alzheimer's Disease
- Progressive Primary Aphasia
- Early or Mild State
|
- Device: transcranial Direct Current Stimulation (tDCS)
|
Interventional |
Not Applicable |
- Centre Hospitalier Universitaire de Besancon
- Centre Hospitalier Universitaire Dijon
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- change from baseline cognitive functions at 3 weeks
|
52 |
All |
60 Years and older (Adult, Senior) |
NCT02873546 |
API/2011/24 |
ALSTICO |
July 19, 2013 |
January 31, 2018 |
July 31, 2018 |
August 19, 2016 |
October 13, 2017 |
|
- CHU Besancon - Clinical Psychiatric Department
Besancon, France - Hopital Universitaire Dijon
Dijon, France - Assistance Publique - Hôpitaux Paris
Paris, France
|
Create an RSS feed from your search for:
Download the search results for: